TriSalus Life Sciences, Inc. $TLSI Shares Bought by Empire Financial Management Company LLC

Empire Financial Management Company LLC raised its stake in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) by 316.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 300,275 shares of the company’s stock after purchasing an additional 228,248 shares during the quarter. Empire Financial Management Company LLC owned 0.49% of TriSalus Life Sciences worth $1,201,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. First Light Asset Management LLC acquired a new stake in shares of TriSalus Life Sciences during the first quarter worth $20,267,000. Nantahala Capital Management LLC grew its position in TriSalus Life Sciences by 1.5% in the 4th quarter. Nantahala Capital Management LLC now owns 2,070,827 shares of the company’s stock valued at $14,454,000 after buying an additional 30,582 shares during the last quarter. Wasatch Advisors LP acquired a new position in TriSalus Life Sciences in the 1st quarter valued at $5,752,000. Vanguard Group Inc. increased its stake in TriSalus Life Sciences by 42.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock valued at $5,392,000 after buying an additional 345,186 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC raised its position in TriSalus Life Sciences by 32.1% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock worth $5,957,000 after buying an additional 265,618 shares during the last quarter. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Stock Up 0.2%

TriSalus Life Sciences stock opened at $4.33 on Wednesday. The company has a debt-to-equity ratio of 2.58, a current ratio of 5.78 and a quick ratio of 5.46. TriSalus Life Sciences, Inc. has a 1-year low of $2.20 and a 1-year high of $7.95. The company has a market cap of $265.95 million, a PE ratio of -3.07 and a beta of 0.43. The stock’s 50 day moving average price is $3.93 and its 200 day moving average price is $4.36.

Insiders Place Their Bets

In related news, Director Mats Wahlstrom purchased 60,000 shares of the stock in a transaction dated Friday, May 15th. The shares were acquired at an average cost of $2.53 per share, with a total value of $151,800.00. Following the purchase, the director directly owned 147,555 shares in the company, valued at $373,314.15. This trade represents a 68.53% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Mary T. Szela purchased 39,682 shares of the business’s stock in a transaction dated Friday, May 15th. The stock was bought at an average price of $2.59 per share, with a total value of $102,776.38. Following the acquisition, the chief executive officer directly owned 1,065,215 shares in the company, valued at approximately $2,758,906.85. This represents a 3.87% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders acquired 719,682 shares of company stock worth $1,804,176. 16.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have recently commented on TLSI shares. Lake Street Capital reduced their target price on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Weiss Ratings lowered shares of TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $7.50.

TriSalus Life Sciences Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.